Engineering a new generation of ophthalmic medicines

About Us

Deploying a first-in-class technology to enable best-in-class ophthalmic medicines. 

Valitor is initially focused on improving patient outcomes in ophthalmology and vision-threatening diseases by conquering long-standing limitations of traditional biologic medicines. By leveraging its multivalent biopolymer technology, the company can take bioactive molecules and engineer best-in-class medicines with extended therapeutic durability. Valitor is using proven targets for ocular diseases to advance best-in-class medicines that maximize the clinical impact for patients.

Durable treatment for vision-threatening diseases

Long-acting VLTR-559 being developed for wet AMD 

Interchangeable platform for efficient pipeline 

Our Team

We have brought together seasoned biotechnology executives, innovative bioengineers and scientists, and leading drug developers to develop better medicines for patients.

Management

Michael Ostrach, JD

Interim CEO

Wesley Jackson, PhD

President, Chief Scientific Officer & Member of the Board

William S. (Sandy) White, PharmD, MBA

Executive Development Advisor

Omkar Joshi

Omkar Joshi, PhD

Senior Vice President of Technical Operations

Board of Directors

Technology

Valitor’s Multivalent Polymer (MVP) technology platform was created for improved therapeutic potency, durability, and safety.

Valitor’s groundbreaking technology platform is based on proprietary multivalent biopolymers that can be loaded with multiple copies of bioactive molecules. The biopolymers and bioactive molecules are interchangeable, which enables Valitor to assemble novel macromolecular entities that are engineered to overcome a multitude of specific drug design challenges for their target indications. This approach allows for independent control of multiple drug attributes, including pharmacokinetic/ pharmacodynamic properties, improved target engagement/tissue localization, therapeutic durability, and improved safety.

The initial focus of the company is to apply its technology to develop best-in-class therapies for multiple indications in ophthalmology, but the broad potential applicability of the platform can lead to rapid pipeline expansion and partnering opportunities, such as for the treatment of cancer or joint diseases.

Engineered to overcome the limitations of conventional therapeutics:

Extended Target Tissue Retention (superior pharmacokinetics) 

Protection from Deactivation/Reactivity (superior pharmaco-stability)

Engineered for High Potency (superior pharmacodynamics)

Pipeline

Novel compounds have shown multiple-fold increases in potency and tissue retention (half-lives) with excellent preclinical safety.

Valitor’s lead development candidate, VLTR-559, is a long-acting treatment for wet age-related macular degeneration (AMD). Wet AMD is a degenerative eye disease caused by the growth of abnormal blood vessels in the eye which leak into the retina. Anti-VEGF therapy works by blocking a protein that inhibits the disease pathology. It is the gold-standard treatment for wet AMD, providing the most effective vision protection. However, current anti-VEGF treatments require a high burden of intravitreal injections, and frequent office visits for disease monitoring are needed to prevent losses in efficacy over the long-term. 

We are developing a next-generation anti-VEGF therapy that will enable reliable dosing only twice yearly, with the overall goal of improving long-term efficacy. In preclinical studies, VLTR-559 exhibited potency that was consistent with approved anti-VEGF therapies and remained in the ocular tissues three to four times longer, demonstrating unprecedented durability at the target site. 

Valitor is exploring additional programs through collaborations.  

Investors

Awards

Careers

We’re motivated by the opportunity to make an impact.

We have established a corporate culture based on collaboration, communication and creation. We are here to create new medicines for patients, meaningful experiences for employees and value for stakeholders. 

For our employees, we offer an attractive compensation package along with medical, dental, and vision insurances. We also enjoy spending time together at company events and we take pride in being responsible members of the community through company-hosted volunteer work and STEM-related activities. 

Job openings

We are not seeking to fill any positions at this time, but we are always interested in qualified candidates. Feel free to send your resume and cover letter to careers@valitorbio.com